Preface
In 1957, a Streptomyces strain, the ME/83 (S.mediterranei), was isolated in the Lepetit Research Laboratories from a soil sample collected at a pine arboretum near Saint Raphaêl, France. This drug was the base for the chemotherapy with Streptomicine, which demonstrated in 1980 to have a 100 per cent efficacy rate after being used together with two or three other drugs during the first two months of treatment in addition to an extra four month treatment combined with Isoniazid. The euphoria generated by the success of this regimen lead to the idea that TB eradication would be possible by the year 2000. Thus, any further drug development against TB was stopped. Unfortunately, the lack of an accurate administration of these drugs originated the irruption of the drug resistance in Mycobacterium tuberculosis. Once the global emergency was declared in 1993, seeking out new drugs became urgent. In this book, diverse authors focus on the development and the activity of the new drug families.
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Background
Tuberculosis is the world's second deadliest infectious disease, with nearly 9.3 million new cases diagnosed in 2007. According to the WHO, an estimated 1.8 million people died from TB in 2007. One-third of the world's population is infected with the TB bacillus and current treatment takes 6-9 months. The current TB vaccine, Bacille Calmette-Guérin (BCG), developed almost 90 years ago, reduces the risk of severe forms of TB in early childhood but is not very effective in preventing pulmonary TB in adolescents and adults -the populations with the highest rates of TB disease. TB is changing and evolving, making new vaccines more crucial for controlling the pandemic. Tuberculosis is now the leading cause of death for people living with HIV/AIDS, particularly in Africa. Multidrug-resistant TB (MDR-TB) and extensively drug-resistant TB (XDR-TB) are hampering treatment and control efforts. New control measures, diagnostic tools and guidelines for treatment as well as development of new drugs and vaccines have been made a priority and the battle is now raging to restore the grip on the magement and control of MDR/XDR TB. Winning the battle against tuberculosis will depend on the outcomes of the extensive research that is on going to produce new, more effective and fast acting diagnostic tools, drugs and vaccines.
Drug-resistant TB
Drug-resistant TB is a result of mycobacterial strains that do not respond to drug treatment. Drug resistance has in the recent past become a serious global public health problem especially in the populations of the poor countries of the world. Multidrug-resistant tuberculosis (MDR-TB) refers to organisms that are resistant to at least two of the first-line drugs, isoniazid (INH) and rifampin, (RIF). In recent years, the world has seen a rapidly emerging epidemic of drug-resistant TB or multi drug-resistant (MDR-TB) and/or extensively drug-resistant XDR-TB ), which is highly lethal and extremely expensive leave alone being complicated to treat. Extensively drug-resistant tuberculosis (XDR-TB) is a type of multidrug-resistant tuberculosis (MDR-TB) that is resistant to two of the first-line drugs -isoniazid and rifampicin -as well as to the second-line medications that include a fluoroquinolone such as ciprofloxacin and at least one of the injectable drugs which may be an aminoglycoside such as amikacin or kanamycin, or a polypeptide like capreomycin, or a thioamides such as ethionamide, or cycloserine or p-aminosalicylic acid.
Because the treatment regimen for TB is long and complex, many patients are unable to complete the course of treatment, enabling their disease to develop drug-resistance. Once a drug-resistant strain has developed, it can be transmitted directly to others. XDR TB being resistant to the front-line drugs and two or more of the six classes of second-line drugs, this makes it virtually untreatable and HIV positive people are particularly at a greater risk. Therefore, XDR TB could have a bigger impact on developing nations considering the fact that there is high prevalence of HIV and lack of capacity to quickly and effectively diagnose and identify the disease. To prevent XDR-TB from spreading, there is an urgent need for new diagnostic tools and new and more effective anti TB drugs and vaccines to be developed. An estimated $5bn is required to confront the spread of DR TB.
Inadequate treatment
The current first-line TB drug regimen of four drugs is nearly 50 years old, takes six to nine months to complete and has significant side effects. Very often, these shortcomings cause patients to default on their treatment which, consequently, results in resistance to TB drugs which then spreads throughout the world. Treatment for MDR-TB or XDR-TB can last up to 30 months, consists of many drugs, (including injectables), many of which have significant side effects, are extremely expensive and resource-intensive to deliver. With the rapid and lethal spread of drug-resistant TB, expediting the development of new, simpler and more effective drug regimens is now a major public health emergency.
Nature of resistance
In a study conducted by Ioerger et al.,(2009) titled "Genome Analysis of Multi-and Extensively-Drug-Resistant Tuberculosis from KwaZulu-Natal, South Africa", which was designed to investigate the causes and evolution of drug-resistance, it was observed that polymorphisms among the strains was consistent with the drug-susceptibility profiles, in that well-known mutations correlated with resistance to isoniazid, rifampicin, kanamycin, ofloxacin, ethambutol, and pyrazinamide. It was however, realised that the mutations responsible for rifampicin resistance in rpoB and pyrazinamide in pncA are in different nucleotide positions in the multi-drug-resistant and extensively drug-resistant strains, which was taken to be an indication that they acquired these mutations independently, and that the XDR strain could not have evolved directly from the MDR strain though it could have arisen from another similar MDR strain.
The researchers reported that the MDR and XDR strains contain typical mutations in gyrA, rpoB, rrs, katG, and the promoter of inhA that explain resistance to fluroquinalones, rifampicin, kanamycin, and isoniazid. Although susceptibilities to ethambutol and pyrazinamide were not determined clinically, mutations in embB and pncA were observed as well. They further argued that the fact that the MDR and XDR strains have different mutations in rpoB and pncA suggests that they arose separately, and that these mutations were acquired independently after divergence. This observation contradicts the hypothesis that the XDR strain might have evolved directly from the MDR strain (though it could have arisen from another similar MDR strain). While resistance to streptomycin is usually associated with mutations in rpsL or rrs, the KZN MDR and XDR strains showed a rare 130 bp deletion in gidB. Although recent studies have begun to show that mutations can cause low-level resistance to streptomycin, through abbrogation of ribosomal methylation, this mutation was unique and had never been reported before.
Consistent with what was already known, the researchers found that only the XDR strain KZN-R506 showed a mutation in rrs, the 16S rRNA, at position 1400, which explains the kanamycin resistance as put forward by Suzuki et al., (1998) and that only the XDR strain had the A90V mutation in gyrA responsible for resistance to fluoroquinolones as presented by Aubry et al., (2006) . They further reported that the mutation at 1400 in rrs which is the most commonly observed mutation associated with kanamycin resistance, found in 60% of rifampicin-resistant clinical isolates was consitent with findings of Suzuki et al., (1998) . The A90V in gyrA, the second-most frequently observed mutation conferring fluoroquinolone resistance, found in 24% of fluoroquinolone-resistant clinical isolates, is also reported to show agreement with the work of van Doorn et al., (2008) on fluoroquinolone resistance.
With respect to isoniazid (INH) resistance, it is also reported that both strains have the mutation of S315T in katG, the catalase/peroxidase that activates the pro-drug isoniazid as reported by Zang et al.,(1992) . The finding that this is the most frequently observed mutation associated with isoniazid resistance was also consistent with the report by Hazbón et al., (2006) and Pym et al.,(2002) . The role of the c-15t inhA promoter mutation, and mutations in katG in ETH/INH co-resistance is also presented as put forward by Morlock et al., (2006) Resistance to rifampicin (RIF) can be explained by mutations in rpoB (beta-subunit of RNA polymerase). The mutation of Asp 435 in rpoB, was observed to confer rifampicin-resistance as put forward by Ramaswamy and Musser (1998) . Ioerger et al.,(2009) further report that this is in the core 507-533 region, in which numerous mutations have been observed to cause resistance to RIF, although they agree that mutations at other sites in this region are more frequent. However, they report that the two Kwazulu Natal strains have different mutations within the same codon, leading to different amino acid substitutions. Strain KZN-V2475 was found to have a G->T substitution in frame 1, producing D435Y, and KZN-R506 with an A->G substitution in frame 2, producing D435G, a case that led the researchers to suggest that the two strains acquired rifampicin resistance independently. They also noted that the XDR strain, KZN-R506, contains two additional mutations in rpoB, L452P and I1106T; the former also being thought to cause RIF-resistance, while the latter does not.
Ioerger et al.,(2009) further contend that streptomycin (STR) resistance is most likely due to a 130 bp deletion in gidB found in both MDR and XDR strains, but not the wild-type. The classic STR-R mutations that have been correlated with streptomycin-resistance in the 530-loop or 915-region of rrs, the 16S ribosomal RNA, or in rpsL, the ribosomal protein S12, were not observed in either strain. However, they also state that mutations in these two genes explain only about 70% cases of STR resistance in clinical isolates (Sreevatsan et al., 1997) implying that there must be other loci that can be responsible. They further add that, despite the mutations in gidB having previously been observed in clinical isolates of M. tuberculosis by Nishimura et al., (2007) that, this 130 bp deletion is distinct from every other gidB mutation previously reported. They report that the 130 bp gidB deletion observed in the KZN MDR and XDR strains spans amino acids 50-93, which encompasses the SAM-binding site (Romanowski et al., 2002) and causes a frame shift for C-terminal remainder, which is presumed to abbrogate function completely. They report that both strains also show classic mutations in embB, pncA, and the promoter region of ethA, which are associated with resistance to ethambutol (EMB), pyrazinamide (PZA), and ethionamide (ETH), though susceptibility to these drugs was not tested. It is further reported that the M306V mutation in the transmembrane protein embB is one of the most frequently observed mutations in EMB-resistant strains as reported by Sreevatsan et al.,(1997) and that this mutation putatively prevents ethambutol from interfering with biosynthesis of the arabinogalactan layer in the cell wall. In the case of pncA, they further report that the two drug-resistant KZN strains showed different mutations in pncA, a pyrazinamidase, which is thought to be involved in nicotinamide biosynthesis. They futher report that the MDR strain KZN-V2475 has a G132A mutation, and that mutations of this residue have previously been reported to cause resistance to PZA Sreevatsan et al., (1997) . They further report that strain KZN-R506 has a frame-shift mutation in amino acid 152 caused by an insertion of 1 bp, and missense mutations that cause resistance that have been observed downstream of this site and that they believe that the C-terminus of the 186-residue gene product must be important. They add that the two drug-resistant strains also share a mutation at position −8 upstream of the translational start site of ethA, which is a monooxygenase that activates thioamides such as ethionamide, isoxyl, and thioacetazone as pro-drugs as reported by Dover et al.,(2007) . The researchers further contend that a mutation in the upstream region could potentially confer resistance by increasing expression although susceptibility of the KZN strains to these drugs was not determined It is further reported by the study that the MDR and XDR strains contain typical mutations in gyrA, rpoB, rrs, katG, and the promoter of inhA that explain resistance to fluroquinalones, rifampicin, kanamycin, and isoniazid. Mutations in embB and pncA were also observed. It is further argued that the fact that the MDR and XDR strains have different mutations in rpoB and pncA which suggests that they arose separately, and that these mutations were acquired independently after divergence. The researchers further report that, the Kwazulu Natal MDR and XDR strains studied showed a rare 130 bp deletion in gidB although resistance to streptomycin is usually associated with mutations in rpsL or rrs. The researchers coclude by recommending further analysis and comparison of the genome sequences they have reported in order to bring out a better understanding of the nature of the virulence XDR-TB strains.
Epidemiology of drug-resistant TB
In South Africa, an epidemic of XDR-TB was reported in 2006 as a cluster of 53 patients in a rural hospital in KwaZulu-Natal of whom 52 died -Tugela Ferry case. What was particularly worrying was that the mean survival from sputum specimen collection to death was only 16 days and that the majority of patients had never previously received treatment for tuberculosis. This was the epidemic for which the acronym XDR-TB was first used, although TB strains that fulfil the current definition have been identified since then, though retrospectively. This was the largest group of linked cases ever found; after the initial report in September 2006, cases have now been reported in most provinces in South Africa, the neghbouring countries and the world at large, with more than 50 countries on all the inhabited continents having reported XDR-TB cases.
MDR/XDR-TB can develop in the course of the treatment of fully sensitive TB and this is always the result of patients missing doses or failing to complete a course of treatment.
Although there are reports that these resistant strains appear to be less fit and less transmissible, the high mortality rate especially where there is co-infection with HIV or during use of immunosuppressive drugs, this warrants that the epidemic has to be taken seriously. There is strong evidence that the spread of XDR-TB strains is very much associated with a high prevalence of HIV and poor infection control, and in some countries the upsurge of XDR-TB has been attributed to mismanagement of cases or poor patient compliance with drug treatment.
XDR-TB does not respond to any of the drugs currently available in most developing countries for first-or second-line treatment. Considering the fact the problem is wide spread globally, strict isolation procedures have been suggested to mitigate rapid spread of XDR-TB. The World Health Organization (WHO) recommends improving basic TB care to prevent emergence of resistance, the development of proper laboratories for detection of resistant cases, and when drug-resistant cases are found, it recommended prompt and appropriate treatment to prevent further transmission.
Collaborative care for both HIV and TB is also recommended to help limit the spread of tuberculosis, both sensitive and resistant strains. The spread of drug-resistant cases has also been linked to overcrowding in places such as seen in prison populations, although the major reason for the development of resistance is poorly managed TB care which may be in form of poor patient compliance, inappropriate dosing or prescribing of medication, poorly formulated medications, and/or an inadequate supply of medication.
Challenges presented by MDR/XDR TB
First, research has revealed that drug-susceptible (regular) TB and MDR/XDR TB are transmitted in the same way. Transmission of XDR TB is in clusters and follows similar transmission patterns as ordinary TB. This makes it difficult to put appropriate barriers to the transmission of the deadly strains. To make matters worse, proper diagnosis involving culture and sensitivity tests is the most commonly used diagnostic method especially in the poor countries. This may take from 6 to 16 weeks, before XDR TB is confirmed during which time it is likely to have spread to other patients and possibly health workers. There have been no new diagnostic tests invented for many years and therefore most laboratories in these areas have limited capacity to respond to XDR-TB. Most laboratories, especially those in developing countries lack the facilities and guidelines for the use of conventional and rapid culture-based or molecular methods for detection of M. tuberculosis and drug resistance and this impedes the widespread use of these tests. The laboratory confirmation of TB in HIV-infected persons is even more difficult and time consuming and highly sensitive and sophisticated and requires technically challenging diagnostic tests that are not universally available in all settings with a high burden of HIV and TB. There is, therefore, poor surveillance especially in the poor developing countries and this presents serious difficulties in identifying and locating the XDR TB cases. A further complication is that TB affects mostly poor people who live in places where health care is not easily accessible and where the patients have to pay for their own transportation
The next challenge is that there are limited treatment options for XDR-TB especially in the developing countries and this makes the disease virtually untreatable. Considering the fact the majority of patients infected with XDR-TB are co infected with HIV/AIDS and that coinfection has been found to be virtually 100% fatal, this makes the situation more serious. In spite of this serious threat, the world is not responding fast enough and with enough resources as was the case with SARS, avian flu or swine flu. Stop TB estimates that through 2015, it will take about $2.4 billion for further discovery and early-stage development work and another $2.4 billion for clinical trials for new anti TB drugs. Considering the fact that the currently available resources are believed to total about $600 million, this leaves a substantial funding gap. More funding has to be directed towards research and development of new TB drugs and vaccines if the pandemic is to be defeated effectively.
With regard to anti-tuberculosis drugs and vaccines, the world's only vaccine (BCG) is almost 100 years old and only effective in children and for over 40 years there has been no new TB drug put on the market. This may be attributed to the high rates of failures of new drugs at clinical trials but it could also partly be due to complacency that tuberculosis was a defeated disease whose prevalence was on the decline especially in the USA. Another handicap has been that clinical trials required to register a TB drug can take a minimum of 6 years, much longer than trials for other infectious diseases.
A further complication is from drug-drug interactions in patients with TB/HIV co-infection. This is a serious hindering factor in finding treatments for people co-infected with TB and HIV. For example it is reported that rifampicin, which inhibits RNA polymerase, interacts with cytochrome P450 isozyme and causes some HIV drugs to be cleared quickly. To make matters worse clinicians, laboratory technologists, health-care professionals, public health officials, and policy makers do not possess up-to-date knowledge of what constitutes appropriate laboratory capabilities and capacities.
The global MDR/XDR response plan 2007-2008
Objectives for the Response were the following: (1) Strengthen basic activities to control TB and HIV/AIDS, as detailed in the Stop TB Strategy; (2) Scale-up the programmatic management of MDR-TB and XDR-TB to reach the targets set forth in the Global Plan; (3)Strengthen laboratory services for adequate and timely diagnosis of MDR-TB and XDR-TB; (4) Expand surveillance of MDR-TB and XDR-TB to better understand the magnitude and trends of drug resistance and the links with HIV; (5) Foster sound infection control measures to avoid MDR-TB and XDR-TB transmission to protect patients, health workers, others working in congregate settings, and the broader community, especially in high HIV prevalence settings; (6) Strengthen advocacy, communication and social mobilization for sustained political commitment and a patient centred approach to treatment; (7) Pursue resource mobilization at global, regional and country levels to ensure that necessary resources are available; and (8) Promote research and development into new diagnostics, drugs, vaccines, and operational research on MDR-TB management to shorten treatment. (Adopted from: WHO Report,2007) 
Treatment of MDR/XDR -TB

Monitoring DOTS-plus
The WHO extended the DOTS programme in 1998 to include the treatment of MDR-TB (called "DOTS-Plus"). Implementation of DOTS-Plus requires the capacity to perform drugsusceptibility testing and the availability of second-line agents, in addition to all the requirements for DOTS. DOTS-Plus is therefore much more resource intensive than DOTS, and requires much greater commitment from countries wishing to implement it. Resource limitations mean that the implementation of DOTS-Plus may lead inadvertently to the diversion of resources from existing DOTS programmes and a consequent decrease in the overall standard of care (Dauby et al., 2011; Tam et al.,2009; Li et al., 2006) .
Monthly surveillance until cultures convert to negative is recommended for DOTS-Plus, but not for DOTS. If cultures are positive or symptoms do not resolve after three months of treatment, it is necessary to re-evaluate the patient for drug-resistant disease or nonadherence to drug regimen. If cultures do not convert to negative despite three months of therapy, some physicians may consider admitting the patient to hospital so as to closely monitor therapy.
Management of TB/HIV co-infection
In patients with HIV, treatment for the HIV should be delayed until TB treatment is completed, if possible. The current UK guidance, provided by the British HIV Association, is that for a CD4 count over 200, treatment should be delayed until the six months of TB treatment are complete; for a CD4 count of 100 to 200, treatment should be delayed until the initial two-month intensive phase of therapy is complete ; while for a CD4 count less than 100, the situation is unclear and they recommend clinical trials to examine the issue. There is need for patients in this category to be managed by a specialist in both TB and HIV so that they are not compromised for either disease.
If HIV treatment has to be started while a patient is still on TB treatment, it is recommended that the advice of an HIV specialist should be sought. In general, reports say that there is no significant interactions with the NRTI's. Nevirapine should not be used with rifampicin. Efavirenz may be used, but the dose used depends on the patient's weight (600 mg daily if weight less than 50 kg; 800 mg daily if weight greater than 50 kg). Efavirenz levels should be checked early after starting treatment. The protease inhibitors should be avoided if at all possible because patients on rifamycins and potease inhibitors have an increased risk of treatment failure or relapse. The WHO also warns against using thioacetazone in patients with HIV, because of the 23% risk of potentially fatal exfoliative dermatitis.
Specific treatment of MDR-TB
The treatment and prognosis of MDR-TB are much more akin to that for cancer than to that for infection. It has a mortality rate of up to 80%, which depends on a number of factors, including: (1) How many drugs the organism is resistant to (the fewer the better); (2) How many drugs the patient is given (patients treated with five or more drugs do better); (3) Whether an injectable drug is given or not (it should be given for the first three months at least); (4) The expertise and experience of the physician responsible; (5) How co-operative the patient is with treatment (treatment is arduous and long, and requires persistence and determination on the part of the patient) ; and (6) Whether the patient is HIV positive or not (HIV co-infection is associated with an increased mortality).
Treatment courses take a minimum of 18 months and may last for years; it may require surgery, though death rates remain high despite optimal treatment. That said, good outcomes are still possible. Treatment courses that are at least 18 months long and which have a directly observed component can increase cure rates to 69%.
Treatment of MDR-TB must be done on the basis of sensitivity testing since it is impossible to treat such patients without this information. When treating a patient with suspected MDR-TB, the patient should be started on streptomycin, isoniazid, rifampicin, ethambutol, pyrazinamide + moxifloxacin + cycloserine (SHREZ+MXF+cycloserine) pending the result of laboratory sensitivity testing. A gene probe for rpoB is available in some countries and this serves as a useful marker for MDR-TB, because isolated RMP resistance is rare, except when patients have a history of being treated with rifampicin alone. If the results of a gene probe (rpoB) are known to be positive, then it is reasonable to omit RMP and to use SHEZ+MXF+cycloserine. The reason for maintaining the patient on INH despite the suspicion of MDR-TB is that INH is so potent in treating TB that it would be irrational to omit it until there is microbiological proof that it is ineffective. There are also probes available for isoniazid-resistance (katG and mabA-inhA), but these are less widely available.
When sensitivities are known and the isolate is confirmed as resistant to both INH and RMP, five drugs should be chosen in the following order (based on known sensitivities):
(1) an aminoglycoside such as amikacin, kanamycin or a polypeptide antibiotic such as capreomycin; (2) pyrazinamide; (3) ethambutol; (4) a fluoroquinolones (moxifloxacin is preferred and ciprofloxacin should no longer be used]); (5) rifabutin; (6) cycloserine; (7) a thioamide: prothionamide or ethionamide; (8) PAS; (9) a macrolide such as clarithromycin; (10) linezolid; (11) high-dose INH (if low-level resistance); (12) interferon-γ; (13) thioridazine; and (14) meropenem and clavulanic acid. Drugs near the top of the list are more effective and less toxic while drugs placed near the bottom of the list are less effective or more toxic, or more difficult to obtain.
Resistance to one drug within a class generally means resistance to all drugs within that class, but a notable exception is rifabutin for which rifampicin-resistance does not always mean rifabutin-resistance and the laboratory should be asked to test for it. It is only possible to use one drug within each drug class and if it is difficult to find five drugs to use then the clinician can request that high level INH-resistance be looked for. If the strain has only low level INH-resistance (resistance at 1.0 µg/ml INH, but sensitive at 0.2 µg/ml INH), then high dose INH can be used as part of the regimen.
When counting drugs, PZA and interferon are counted as zero i.e. when adding PZA to a four drug regimen, you must still choose another drug to make five. It is not possible to use more than one injectable (capreomycin or amikacin), because the toxic effect of these drugs is additive: if possible, an aminoglycoside should be given daily for a minimum of three months (and perhaps thrice weekly thereafter). Ciprofloxacin should not be used in the treatment of tuberculosis if other fluoroquinolones are available.
